{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-004634","form_type":"8-K","ticker":"PLSH","cik":"0001552189","company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.542491+00:00","generated_at":"2026-06-19T13:45:08.916760+00:00","sec_items":["1.01","2.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Panacea Life Sciences agrees to repay $385K convertible note via cash and equity conversion","bullets":["Company to pay $135,000 funded under CEO line of credit on Feb 13, 2023; $100,000 by June 30, 2023.","Conversion of 540,000 common shares at fixed price of $0.25 per share to satisfy remaining balance.","Note Payoff Agreement dated Feb 9, 2023 amends prior Share Exchange Agreement from March 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-004634","json":"https://secwatch.observer/filing/0001493152-23-004634.json","markdown":"https://secwatch.observer/filing/0001493152-23-004634.md","text":"https://secwatch.observer/filing/0001493152-23-004634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1552189/000149315223004634/0001493152-23-004634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1552189/000149315223004634/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:45:08.916760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ffad7128714cc0047a860c674cf1c425b8ed2a26","claim":"PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Exchange of 350 shares of Series A Preferred Stock for Senior Convertible Note of $385,000, subseque (effective 2022-03-03).","evidence_excerpt":"On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1552189/000149315223004634/0001493152-23-004634-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"institutional investor"},{"label":"Value","value":"Exchange of 350 shares of Series A Preferred Stock for Senior Convertible Note of $385,000, subseque"},{"label":"Effective","value":"2022-03-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}